U.S. Markets open in 5 hrs 29 mins

(BOTA)


NasdaqGS . Currency in USD
Add to watchlist
Interactive chart
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Researchlast year

    BOTA: Clinical Trial Update

    By Anita Dushyanth, PhD NASDAQ:BOTA Following the successful Single Ascending Dose (SAD) study, Biota (NASDAQ:BOTA) completed the Phase 1 multiple ascending dose (MAD) study in the beginning of 2016. The ...

  • Biota Pharmaceuticals, Inc. Earnings Analysis: Q2, 2016 By the Numbers
    Capital Cubelast year

    Biota Pharmaceuticals, Inc. Earnings Analysis: Q2, 2016 By the Numbers

    Click here to see latest analysisBiota Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2015.We analyze the earnings along side the following peers of Biota Pharmaceuticals, Inc. – GlaxoSmithKline plc Sponsored ADR (GSK-US) that have also reported for this period.HighlightsNarrowing of operating margins contributed to decline in earnings.The table below shows the […] (Read more...) The post Biota Pharmaceuticals, Inc. Earnings Analysis: Q2, 2016 By the Numbers appeared first on CapitalCube.

  • Zacks Small Cap Researchlast year

    BOTA: Initiating Coverage on Biota Pharma

    Lower respiratory tract infections are induced by various viruses. During the beginning of fall and spring seasons, these viruses contribute significantly to the incidence of viral respiratory tract infections.